Skip to main content
SpringerLink
Log in

Management of HCV Infection

  • Chapter
  • First Online:
Handbook of Hepatitis C

  • 1061 Accesses

Abstract

There has been a tremendous shift in the landscape of hepatitis C virus (HCV) management with the advent of direct acting antivirals (DAAs). HCV therapy with DAAs has dramatically increased the efficacy of therapy, reduced side effects, and reduced treatment duration. However, due to high pricing strategies, this progress has come at a high financial cost, limiting the accessibility of these novel drugs to patients with advanced stages of hepatitis C.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Girardin F, Goossens N, Vernaz N, Negro F. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C]. Rev Med Suisse. 2015;11:1610–1612, 1614–1616.

    Google Scholar 

  2. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.

    Google Scholar 

  3. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236.

    Google Scholar 

  4. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.

    Google Scholar 

  5. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–2509.

    Google Scholar 

  6. Poordad F, Hezode C, Trinh R, et al, ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Eng J Med. 2014;370:1973–1982.

    Google Scholar 

  7. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–264.

    Google Scholar 

  8. Manns MP, Wedemeyer H, CornbergM. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–1359.

    Google Scholar 

  9. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med. 2011;364:2405–2416.

    Google Scholar 

  10. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Eng J Med. 2011;364:1195–1206.

    Google Scholar 

  11. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403–413.

    Google Scholar 

  12. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414–426.

    Google Scholar 

  13. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2013;146:430–441.

    Google Scholar 

  14. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.

    Google Scholar 

  15. Kwo P, Gitlin N, Nahass R, et al. LP14: A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1. J Hepatol. 2015;62 (Suppl 2):S270.

    Google Scholar 

  16. Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Eng J Med. 2015;373:1886–1888.

    Google Scholar 

  17. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Eng J Med. 2014;370:1879–1888.

    Google Scholar 

  18. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Eng J Med. 2014;370:1594–1603.

    Google Scholar 

  19. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.

    Google Scholar 

  20. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Eng J Med. 2014;370:211–221.

    Google Scholar 

  21. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13:401–408.

    Google Scholar 

  22. Zeuzem S, Dusheiko GM, Salupere, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Eng J Med. 2014;370:1993–2001.

    Google Scholar 

  23. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.

    Google Scholar 

  24. Moreno C, Hezode C, Marcellin P, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol. 2015;62:1047–1055.

    Google Scholar 

  25. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049–1054.

    Google Scholar 

  26. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.

    Google Scholar 

  27. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61:769–775.

    Google Scholar 

  28. Jensen DM, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Abstract presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7–11, 2014; Boston, US.

    Google Scholar 

  29. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Eng J Med. 2014;370:1889–1898.

    Google Scholar 

  30. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Eng J Med. 2014;370:1483–1493.

    Google Scholar 

  31. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359–365.

    Google Scholar 

  32. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–1614.

    Google Scholar 

  33. US Food and Drug Administration website. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. www.fda.gov/Drugs/DrugSafety/ucm468634.htm. Updated Oct 22, 2015. Accessed Feb 11, 2015.

  34. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403–2412.

    Google Scholar 

  35. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373:2608–2617

    Google Scholar 

  36. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373:2599–2607.

    Google Scholar 

  37. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.

    Google Scholar 

  38. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–1086.

    Google Scholar 

  39. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.

    Google Scholar 

  40. Negro F. Hepatitis C virus epidemiology, pathogenesis, diagnosis, and natural history. In: Zeuzem S, Afdhal NH, ed. inPractice Hepatology. 2015. www.inpractice.com/Textbooks/Hepatology.aspx. Updated July 24, 2015. Accessed Feb 11, 2016.

  41. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88.

    Google Scholar 

  42. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625–633.

    Google Scholar 

  43. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010;17:201–207.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, USA

    Nicolas Goossens

  2. Department of Clinical Pathology, Faculty of Medicine, Geneva University Hospitals, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Geneva University Hospitals, Geneva, Geneve, Switzerland

    Francesco Negro

Authors
  1. Nicolas Goossens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Clément
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Negro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    Nicolas Goossens

  2. University Hospitals and Faculty of Medi, Clinical Pathology, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Division of Gastroenterology and Hepatol, Geneva University Hospital, Geneva 14, Geneve, Switzerland

    Francesco Negro

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Goossens, N., Clément, S., Negro, F. (2016). Management of HCV Infection. In: Goossens, N., Clément, S., Negro, F. (eds) Handbook of Hepatitis C . Adis, Cham. https://doi.org/10.1007/978-3-319-28053-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28053-0_6

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-28051-6

  • Online ISBN: 978-3-319-28053-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation